Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$47.78+0.63 (+1.34%)
Close on Nov 13, 2026Market cap $6.75BP/E –Yield –
Arrowhead Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Arrowhead Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -160.6%. For fiscal 2026 it was -160.6%, against -0.2% the year before. The highest annual figure on record is 40.3% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Sep 30, 2026 | -160.6% | −160.4 |
| FY2025 | Sep 30, 2025 | -0.2% | +16882.2 |
| FY2024 | Sep 30, 2024 | -16882.4% | −16797.1 |
| FY2023 | Sep 30, 2023 | -85.3% | −12.9 |
| FY2022 | Sep 30, 2022 | -72.4% | +29.5 |
| FY2021 | Sep 30, 2021 | -101.9% | −5.8 |
| FY2020 | Sep 30, 2020 | -96.1% | −136.4 |
| FY2019 | Sep 30, 2019 | 40.3% | +377.6 |
| FY2018 | Sep 30, 2018 | -337.3% | −227.9 |
| FY2017 | Sep 30, 2017 | -109.5% | +51505.2 |
| FY2016 | Sep 30, 2016 | -51614.6% | −27546.3 |
| FY2015 | Sep 30, 2015 | -24068.3% | +9434.7 |
| FY2014 | Sep 30, 2014 | -33503.0% | −22773.7 |
| FY2013 | Sep 30, 2013 | -10729.2% | +3654.4 |
| FY2012 | Sep 30, 2012 | -14383.6% | −13327.1 |
| FY2011 | Sep 30, 2011 | -1056.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2026CQ3 2026 | Sep 30, 2026 | -1132.5% | −1123.2 |
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -258.2% | +372.9 |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -180.0% | −248.3 |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | 11.7% | +6935.1 |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -9.3% | +3732.3 |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -631.1% | +50.3 |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | 68.3% | +718.8 |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -6923.4% | −6956.7 |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -3741.6% | −3675.5 |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -681.4% | −410.5 |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -650.5% | −428.2 |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | 33.3% | +4.1 |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -66.1% | +163.1 |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -270.8% | −105.3 |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -222.3% | −157.1 |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | 29.2% | +111.0 |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -229.1% | −131.8 |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -165.5% | +469.0 |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -65.2% | −15.5 |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -81.7% | +2.6 |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -97.3% | −88.2 |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -634.5% | −661.6 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -49.7% | −97.3 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -84.3% | −133.9 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -9.1% | −43.8 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | 27.0% | +122.7 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | 47.6% | +2193.2 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | 49.6% | +2339.1 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | 34.7% | +410.8 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -95.6% | +27.5 |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -2145.5% | −2086.4 |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -2289.5% | −2222.2 |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -376.1% | −99.2 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -123.2% | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -59.1% | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -67.2% | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -276.9% | – |
See a number that looks wrong?